Abstract: Venous thromboembolism (VTE) has become the most common complication in tumor patients and is the second leading cause of death in these patients. The presence of a tumor increases the risks of thrombosis and bleeding. Thus, it is important to have a model capable of effective risk assessment and screening for cancer patients. Cancer patients can be categorized based on risk levels. For low-risk patients, the cost of medical treatment and the risk of bleeding caused by prevention of thrombosis or the sole use of mechanical prevention are less. High-risk patients can benefit from prevention measures. This review presents a comparison between the current VTE risk assessment models and discusses the current situation of cancer-associated VTE, establishment of risk models, and future directions. The review aims to improve the understanding of cancer-associated VTE risk assessment models and provide guidance for the establishment and development of risk models.